Abstract Library

#4316 Combination of sorafenib and everolimus regresses pancreatic neuroendocrine tumour significantly in vitro and vivo

Introduction: PNET is a rare group of highly heterogeneous tumours with neuroendocrine differentiation properties. Everolimus is the most promising drug for progressive well-differentiated pNETs. Sorafenib's anti-tumour activity may involve regulation of the mTOR pathway.

Conference:

Presenting Author: Zheng H

Authors: Zheng H,

Keywords: sorafenib, everolimus, pancreatic neuroendocrine tumour, mTOR,

#4306 EVENET: Randomised phase II trial of everolimus 5mg vs. 10mg daily in patients with neuroendocrine tumours

Introduction: Everolimus 10mg PO daily is approved for patients (pts) with advanced G1/G2 neuroendocrine tumours (NET) but is associated with significant toxicity, including 20% of serious infections in real-world pts. In phase I trials, 5mg/day was sufficient to inhibit the mTOR pathway. Retrospective data suggest that 5mg/day is similarly effective to 10mg/day but less toxic.

Conference:

Presenting Author:

Authors: Riechelmann R, Campos A, Durant L, Bulzico D,

Keywords: everolimus, neuroendocrine tumour, dose optimisation, toxicity,

#4219 MAPK and mTOR pathway activation is associated with chemotherapy resistance and a poor prognosis in G3 advanced NENs

Introduction: Neuroendocrine neoplasms (NENs) comprise a broad spectrum of disease ranging from slowly progressive to highly aggressive carcinomas.

Conference:

Presenting Author: Catoya J

Authors: Catoya J, Anton-Pascual B, Farinea G, Modrego A, La Salvia A,

Keywords: NEN, mTOR/MAPK pathway, molecular profiling, platinum-based,

#4075 A phase II study of Lenvatinib and Everolimus in advanced well-differentiated extra pancreatic neuroendocrine tumors

Introduction: Data suggest that combined inhibition of VEGF and FGF is an effective antiangiogenic strategy and that concomitant inhibition of the mTOR pathway may be further synergistic.

Conference:

Presenting Author: Dasari A

Authors: Dasari A, Qiao W, Halperin D, Stanietzky N, Surabhi V,

Keywords: Extrapancreatic NET, Lenvatinib, Everolimus, Phase II,

#3989 Hypoxia upregulating ACSS2 enhances lipid metabolism reprogramming through HMGCS1 mediated PI3K/AKT/mTOR pathway to promote the progression of pancreatic neuroendocrine neoplasms

Introduction: Pancreatic neuroendocrine neoplasms (pNENs) are relatively rare. Hypoxia and lipid metabolism-related gene acetyl-CoA synthetase 2 (ACSS2) is involved in tumor progression, but its role in pNENs is not revealed.

Conference:

Presenting Author:

Authors: Gu D, Ye M, Zhu G, Bai J, Tang Q,

Keywords: hypoxia, ACSS2, lipid metabolism reprogramming, HMGCS1, PI3K/AKT/mTOR pathway, pancreatic neuroendocrine neoplasm,